Consensus Statements Developed for Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa

According to a study published in Skin Appendage Disorders, expert-derived consensus statements were developed to guide clinicians on COVID-19 vaccination in patients with hidradenitis suppurativa (HS).

Researchers aimed to provide expert consensus recommendations regarding COVID-19 vaccination in patients with HS using a modified Delphi consensus survey. The survey was developed by a committee of 7 dermatologist experts in HS and results were reviewed by the group and revised until a consensus was achieved.

A total of 12 consensus statement were developed by 30 dermatologists, 1 general surgeon, 1 plastic surgeon, and 1 rheumatologist. The consensus highlighted that patients with HS and their close contacts should receive the COVID-19 vaccine and follow preventive measures. HS treatment regimens should not change when receiving the vaccination or after.

“Presently, this expert consensus can guide clinicians on COVID-19 vaccination in HS patients,” concluded the study authors. “These statements shall be updated appropriately as our understanding of COVID-19 and HS improves,” they added.

Reference
Rick JW, De DR, Shih T, et al. Guidance on COVID-19 vaccination in hidradenitis suppurativa patients: a modified Delphi consensus of experts. Skin Appendage Disord. 2022;8(4):287-290. doi:10.1159/000521268